Poly(lactic acid), which has an inherent tendency to form colloidal systems of low polydispersity, and alkylglyceryl-modified dextran -a material designed to combine the non-immunogenic and stabilising properties of dextran with the demonstrated permeation enhancing ability of alkylglycerols -have been combined for the development of nanoparticulate, blood brain barrierpermeating, non-viral vectors. To this end, dextran, that had been functionalised via treatment with epoxide precursors of alkylglycerol, was covalently linked to poly(lactic acid) using a carbodiimide cross-linker to form alkylglyceryl-modified dextran-graft-poly(lactic acid). Solvent displacement and electrospray methods allowed the formulation of these materials into nanoparticles having a unimodal size distribution profile of about 100 -200 nm and good stability at physiologically relevant pH (7.4). The nanoparticles were characterised in terms of hydrodynamic size (by Dynamic Light Scattering and Nanoparticle Tracking Analysis), morphology (by Scanning Electron Microscopy and Atomic Force Microscopy) and zeta potential, and their toxicity was evaluated using MTT and Presto Blue assays. Cellular uptake was evidenced by confocal microscopy employing nanoparticles that had been loaded with the easy-to-detect Rhodamine B fluorescent marker.
Introduction
The extent of neurodegenerative, cerebrovascular, inflammatory, neoplastic and infectious brain diseases is expected to rise with increasing average life expectancy and with the current advances in diagnostic methods. 1 In treating brain ailments, the intravascular route appears attractive compared to other approaches due to the proximity of the brain parenchymal cells to brain capillaries and the large surface area of the brain vessel network. 2 Transport from the blood-stream into the brain however is generally limited by the presence of the blood-brain barrier (BBB), which has an important role in maintaining the specific environment required for neuronal signalling. The presence of tight junctions and efflux proteins, together with processes such as selective abluminal transport and the flow of intracerebral fluid, act additively to restrict entry into the brain of toxins, xenobiotics and molecules endogenous to the circulatory system that may otherwise compromise the homeostasis of the neuronal environment. 3 Among several approaches aimed at overcoming the BBB (including osmotic opening, prodrugs, intracerebral implants, convection-enhanced delivery or focused ultrasound), colloidal systems such as nanoparticles or liposomes are now widely accepted as an effective tool for transporting essential actives into the brain. Although studies in this very active area of research have shown that these carriers may take advantage of the biochemical transport systems present at the barrier level, the mechanism of BBB transport is still under debate.
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Poly(lactic acid) (PLA) is commonly used for various tissue engineering and drug delivery applications not only due to its biodegradability, biocompatibility and to being non-immunoactive, but also due to its capacity to form colloidal systems of low polydispersity. 12, 13 While the hydrophobicity of pure PLA nanoparticles normally leads to a rapid removal from the bloodstream by the reticulo-endothelial system upon iv injection, 14 this shortcoming may be addressed by modification with hydrophilic materials of natural origin, such as dextran. [15] [16] [17] Considered non-toxic and non-immunogenic, dextran has been used historically as a safe plasma expander 18 and also to impart stabilisation in the blood-stream and "stealth" properties to injectable nanoparticles. 19, 20 Among the materials investigated for enhancing drug penetration across the BBB, alkylglycerols have been shown to encourage a strong but transient increase in the transport of actives into the brain. [21] [22] [23] [24] If co-administered into the right internal carotid artery, the same materials have been found to increase brain uptake of certain antineoplastic agents (such as cisplatin and methotrexate) or antibiotics (such as vancomycin and gentamycin) in C6 glioma bearing rats and animals with RG2
implanted tumours. 25, 26 Rationalised by the hypothesis that the assemblage of a drug-carrier system based on dextran that had been modified with alkylglyceryl moieties and the easily biodegradable poly(lactic acid) could promote increased drug permeability towards the brain, we report on the formulation and physicochemical characterisation of nanoparticulate non-viral vectors prepared from alkylglyceryldextrans and poly(acrylic acid) and assess their toxicity and permeability/interaction with in vitro models of the BBB based on mouse and human brain capillary endothelial cells (bEnd3 and hCMEC/D3).
Experimental
General. Dextran from Leuconostoc (MW 6 kDa), dimethyl sulfoxide (DMSO, anhydrous, ≥ 99.9 %), butyloxymethyloxirane (OX4, 95 %), 4-(dimethylamino) pyridine (DMAP, puriss. > 99 %), Zn(BF 4 ) 2 , potassium tert-butoxide (t-BuOK; reagent grade > 97 %), carbonyldiimidazole (CDI, reagent grade), toluene (anhydrous, 99.8 %) were all obtained from Sigma Aldrich, Gillingham, UK.
Poly(lactic acid) (PLA) with free carboxyl group (PLA-02A, MW 15 kDa) was a gift from Purac, Gorinchem, Netherlands. Fast green, Paraformaldehyde, Evans Blue and Rhodamine B were purchased from Sigma Aldrich, Gillingham, UK; Doxorubicin hydrochloride was obtained from
LGM Pharma, Nashville, USA; non-anhydrous solvents were obtained from Fisher Scientific, Loughborough, UK; high purity deionised water was sourced from a PURELAB Optima lab system.
Gentamycin was supplied from Gibco, Paisley, UK; fountain ink (India) was purchased from Pelikan. Unless otherwise specified, all reagents were used as obtained. Solvent removal under reduced pressure was performed using a Büchi Rotovapor R-200 powered with a Sogevac Saskia PIZ 100 vacuum pump equipped with a liquid nitrogen trap. Solvents were degassed using three freeze-thawing cycles. Sonication was performed using a Grant ultrasonic bath XB3 (Farnell, UK). Low speed centrifugation was performed using a Jouan B4i centrifuge equipped with a S40 rotor (4 000 rpm; 2 880 g; 15 min, unless otherwise specified 
Synthesis of alkylglycerol-dextran derivatives (DEX-O4 and DEX-OX 8).
The synthesis of nalkyloxymethyloxiranes (OX-4 and OX-8) was carried out according to a method described previously. 27 Dextran (1.00 g; 6. 
Synthesis of alkylglyceryl dextran-graft-poly(lactic acid) derivatives (PLA-DEX-OX4 and PLA DEX-
OX8) was carried out by a modification of Nagahama's procedure. 16 In a reaction apparatus that was degassed and purged with nitrogen, poly(lactic acid) (PLA, 0.50 g, 0.033 mmol) in anhydrous chloroform (7.0 mL) was added drop-wise to a solution of carbodiimidazole (CDI, 0.11 g, 0.66 mmol) in anhydrous chloroform (5.0 mL). The reaction mixture was stirred for 6 h at room temperature under nitrogen, and then washed with ethanol (10 mL) to remove the excess CDI and imidazole. The resultant precipitate was collected by centrifugation and dried overnight in vacuo (25 °C 
Loading and release studies using fluorescent drug / markers. Fluorescein isothiocyanate (FITC),
Rhodamine B and Doxorubicin free base were loaded following the same methods as for the preparation of nanoparticles (namely solvent displacement and electrospraying, as described above).
Rhodamine B and Doxorubicin free base were dissolved in DMSO (10 % w/w in respect to the polymer); Doxorubicin free base was obtained from commercial hydrochloride salt by treatment with triethylamine followed by extraction with dichloromethane. Drug loading was determined by UVVis spectroscopy following separation of nanoparticles by ultracentrifugation (40 000 rpm; 164 391 g; 30 min, 20°C, Beckman, rotor 70.1 Ti); pellets were freeze-dried, measured for mass and dissolved in DMSO to determine the amount of dye by UV/Vis (measuring at 318 nm for Rhodamine B; 493 nm for FITC; 478 nm for Doxorubicin), and the results were plotted against calibration curves of the same fluorescent molecules obtained in DMSO.
For release studies, the freeze-dried PLA-DEX-OX4 nanoparticles were redispersed (at a concentration of 1.0 mg/mL) in PBS (15 mL, pH 7.4, saline 0.9 %) and transferred into Eppendorf tubes (1.0 mL each) that were then incubated at 37 °C in a shaker / water bath with thermostat.
Tubes were then individually removed at pre-determined time points and centrifuged (13 000 rpm; Table S2 (Supplementary material). Nunclon F 96-well plates were sourced from Thermo Scientific. Cells were observed with an Olympus IX71 inverted phase microscope (images were taken using Olympus Soft Imaging System, UK) and with an LSM 710 confocal microscope (Zeiss, fluorescence excitation at 405 nm, 488 nm and 633 nm; facilitated by a Twin Gate main beam splitter). Cells were counted using either a Vi-CELL XR Cell Viability Analyser (Beckman Coulter, UK) or a haemocytometer. The analysis of well-plates was performed using a POLARstar Optima (BMG Labtech) plate-reader. Electric Cell-substrate Impedance Sensing (ECIS) measurements were conducted with an ECIS Zθ instrument (Applied Biophysics) operating at a frequency range of 2 -32 kHz and using 8 well-arrays type 8W10E.
Cytotoxicity assays. Nanoparticles (formulated from PLA-DEX; PLA-DEX-OX4 and PLA-DEX-OX8) were tested for cytotoxicity against bEnd3 cells (seeding 1×10 4 cells,) using an MTT assay.
Nanoparticles were suspended in modified DMEM (1 mg/mL) and used to incubate with confluent bEnd3 cells (24 h 
In-ovo toxicity investigations. Embryos in their early stage of development (embryos in Hamburger-
Hamilton HH stage 19, day 2; eggs supplied from a local farm after fertilisation and stored prior use at 15 °C in a cold storing room) were employed for these studies. Eggs (n = 6) were placed into an incubator (37 °C, 60-70 % humidity) 48 h prior to nanoformulation treatment. After 72 h in the incubator, a needle was inserted through the eggshell at the narrow apex to remove the excess of egg white. Adhesive tape was used to cover the egg on the top (to prevent the structure from collapsing) and a small oval window was cut into the shell, through the tape. 100 μL of gentamycin in PBS (10 % w/v) was instilled inside the egg as an antibiotic pre-treatment prior to any manipulation. Fountain pen ink was then injected under the embryo to provide a contrast background for easier orientation and manipulation. The vitelline membrane enveloping the embryo was then cut with a forceps to reach the heart area. A thin glass micro-needle (diameter 25 μm) connected to a pneumatic pumping device was used to inject the nanoformulation into the heart of the embryo, close to aorta.
Rhodamine B-loaded PLA-DEX-OX4 nanoformulations (5 μL; 1 mg/mL; Rhodamine loading 1.5 % w/w, by electrospraying) were employed for this study, with a Rhodamine B solution (5 μL; 0.015 mg/mL) used as a control.
A Fast Green solution (1 % v/v, 1 μL) was added to the nanoformulations prior to injection to allow visualising the spread of nanoparticles through the blood stream of the embryos. The egg cavity was instilled again with a dose of the antibiotic (as above), and the shell window was sealed with transparent adhesive tape. The eggs were then further incubated (37 °C, 60-70 % humidity) for 24 h before harvesting the embryos. The embryos were removed from the eggs and cleaned by removing the rest of the vitelline membrane (by forceps), fixed for 15 min in paraformaldehyde solution in PBS (4 % w/v), and embedded in hot gelatine (60 °C). After storing for 2 h at 4 °C, the embryos were removed and sectioned using a vibratome (50 μm slices). The analysis was performed by a confocal microscope (using a 543 nm laser to visualise Rhodamine B).
Cell uptake studies. bEnd3 cells were seeded (5.0×10 4 ) onto glass cover slips previously coated with Matrigel 1.5 mg/mL and incubated for 24 h in 2.0 mL of modified DMEM (composition given in Table S2 (50 μl of PBS containing dispersed nanoparticles in a concentration range 1 -4 mg/mL for PLA-DEX-OX4, and 4 mg/mL PLA-DEX). After incubation with nanoparticles (24 h), the nanoformulation was removed and replaced with fresh media, and well were further monitored for 24 h. ECIS readings were taken continuously for the whole duration of the experiment using an ECIS Zθ instrument (Applied Biophysics, USA) at 2 000 Hz.
Results and discussion
Dextrans were modified by grafting with alkylglyceryl chains (where alkyl was either butyl, pentyl, or octyl) via a nucleophilic substitution reaction with the corresponding alkyloxy-substituted oxirane in an alkaline environment; this was followed by coupling with poly(lactic acid) using carbodiimide chemistry to afford alkylglyceryl-dextran-graft-poly(lactic acid), Figure 1 .
Figure 1
The degree of substitution with alkylglyceryl chains (defined as the number of pendent chains per 100 glucopyranose rings of dextran) was found to be directly dependent on the strength of the base and on the excess of oxirane employed. Various bases (pyridine, DMAP and t-BuOK) were tested: while pyridine's basicity was not sufficient and DMAP yielded only low degrees of substitution (2.1- 
where C4' is the integral of the signal assigned to the alkyl chain CH 3 end group (0.86 ppm; Figure   1 ), and C1 is the integral of the signal assigned to the anomeric proton from of the glucopyranose ring (4.67 ppm).
The degree of substitution varied widely (from 0.7 to 75.1 % for DEX-OX4, and from 16.5 to 38.2 % for DEX-OX8), and it was found to increase with reaction time and with the concentration of base (tBuOK) employed. Since the calculated degree of substitution never exceeded 100 %, and considering that the OH group reactivity in dextran towards alkylation agents is known to decrease in the order C2 > C4 > C3 (likely due to the proximity to the anomeric C1 carbon), [32] [33] [34] [35] it can be reasonably assumed that only the primary hydroxy groups were grafted with alkylglyceryl chains.
Poly(lactic acid) with free carboxylic end group was attached to the alkylglyceryl-modified dextran 
where: a integral of the signal attributed to the CH 3 group in PLA (1.31 ppm) C1 integral of the signal attributed to the anomeric proton of dextran (4.39 -5.17)
The degree of grafting was found to decrease slightly with increasing length of the alkylglyceryl chain used for the hydrophobic modification of dextran: PLA-DEX (130-142 %); PLA-DEX-OX4
(108-120 %); PLA-DEX-OX8 (88-112 %).
The size range of nanoparticles prepared from PLA-DEX-OX4 by solvent displacement was found to be consistent with those reported in the literature for poly(lactic acid) dextran copolymers. 16, 36 The same parameter was found to be dependent on the concentration of polymer in the DMSO solution that had been subjected to dialysis (Figure 2A) , with concentrations below 6 mg/mL affording the smallest particle size (diameter 120 -160 nm). Also, no significant statistical difference was found in the size of nanoparticles obtained from different PLA-conjugated modified dextran polymers (PLA-DEX, PLA-DEX-OX4, PLA-DEX-OX8) using the solvent displacement formulation method at the concentration of 1.0 mg/mL ( Figure 2B ).
Figure 2
Further experiments employing electrospraying techniques where PLA-DEX-OX4 solutions in DMSO (50 mg/mL) were subjected to high voltage electric field resulted in the formation of particles at the 100 -200 nm diameter range. As with nanoprecipitation, this technique requires postpurification of nanoparticles either by dialysis or ultra-centrifugation. A comparison of the characteristics measured for the PLA-DEX-OX4 nanoparticles formulated using different methods (Table 1) suggests that size (as measured in PBS saline 0.9 %, at pH 7.4, by both DLS and NTA) is in all cases suitable for intravascular drug delivery at physiological pH, 37 with the solvent displacement method offering the advantage of higher yields.
Table 1
The pH stability of PLA-DEX-OX4 nanoformulations was investigated by titrating nanoparticles dispersed in ultrapure water while monitoring their size and zeta potential, which at pH 7.4 was in the range -15 to -30 mV for all formulations. Both average size and zeta potential were stable over a wide range of pH values (2 -8), however an increase in size and a gradual agglomeration were noticed near the isoelectric point of poly(lactic acid), as expected from its pK a value (3.1) (Figure 3 ). when comparing these results with those obtained for the same type of nanoparticles in colloidal form are likely due to the hydration of the outer layer and also possibly due to an induced conformational change of polymer chains at the surface of nanoparticles. 38 
Figure 4
Doxorubicin free base, Fluorescein isothiocyanate (FITC), and Rhodamine B free base were employed as drug models and fluorescence markers respectively. The molecules were selected due to their low detection limits and limited photobleaching. They were loaded into PLA-DEX-OX4 nanoparticles prepared by either solvent displacement or by electrospraying, and drug/marker loading was determined by fluorescence measurements; results ( Table 2 ) clearly indicate that electrospraying provides a more efficient loading method compared to solvent displacement. FITC was found to load poorly into PLA-DEX-OX4 nanoparticles and to be released under simulated physiological conditions with a burst effect that was complete within 30 min ( Figure 5 ). In contrast, Rhodamine B and Doxorubicin (both as free base) showed better loading and gradual release 30 to 50 % over several hours. Table 2 Figure 5
Despite recent drug-delivery advances that seem to hold great promise for the treatment of CNS diseases, very little is known about the long-term safety of nanomaterials employed in these studies, therefore testing the toxicity of these nanoformulations in early stages of development is of importance. We found that incubation of mouse brain endothelial cells bEnd3 with poly(lactic acid)-graft-alkylglyceryldextran (PLA-DEX-OXn) nanoparticles (1 mg/mL) for 24 h revealed no significant toxicity induced by these nanoformulations (ANOVA p < 0.05); cell viability following treatment with PLA-DEX, PLA-DEX-OX4 and PLA-DEX-OX8 nanoparticles was about 90 % of that of a PBS control ( Figure 6A ). Experiments with human brain endothelial cells (hCMEC/D3) at different concentrations confirmed the lack of toxicity at short incubation times (3 h) and appeared to suggest that the alkylglyceryl modification of dextran shows a higher viability compared to PLA-DEX ( Figure 6B) ; however, incubation for 24 h revealed a gradual reduction in viability at doses higher than 2 mg/mL (ANOVA, p < 0.05) ( Figure 6C ). Injections into the heart of chicken embryos with nanoformulations prepared from PLA-DEX-OX4
and loaded with Rhodamine B showed that nanoparticles did not aggregate in circulation and did not affect the viability of the embryos; 100 % viability (n = 6) was observed for both control and nanoparticles (as evidenced by the heart function of the embryos) for the duration of the experiment (min. 24 h following injections). No specific patterns were observed in the biodistribution of the fluorescent marker, which appeared to extravasate freely into the embryo as all the endothelial barriers including the BBB are still leaky at this development stage. 39 Most of the fluorescence appeared around blood vessels, and no significant differences were observed in the distribution of Rhodamine B between the two administration methods employed (i.e. as solution, or loaded into nanoparticles and later released during incubation; Figure 7 ). experiments to be readily tolerated by the cells ( Figure 6B ). The data in Figure 9 indicate that at high concentrations (4 mg/ml) there is a non-reversible drop in TEER after 72 h, which may be attributed to cell death (as supported by the decrease in cell viability observed at high nanoparticle concentrations, Figure 6C ). Following nanoparticle removal, TEER levels recovered for all monolayers except those that had been treated with the highest dose of PLA-DEX-OX4 (significant statistical difference for bEnd3 cells at 72 h, ANOVA, p < 0.05, Figure 9A ); this may be attributed to the time-and concentration-dependent toxicity of PLA-DEX-OX4 nanoparticles. No significant dose-response effect could be unmasked when the formulation was tested against human-brain endothelial hCMEC/D3 cells ( Figure 9B ).
Figure 9
Investigations of the capability of PLA-DEX-OX4 nanoparticles to increase drug permeability through mouse and human brain endothelial cell monolayers were carried out using a translocation model system based on a Transwell setup, where the effect of each nanoformulation was assessed using fluorescent FITC-labelled dextran (MW 150 kDa). In a comparison of the two types of models, data suggested that the bEnd3 model was more permeable than that based on hCMEC/D3 cells ( Figure 10) ; the latter may therefore be more suitable for this type of permeability experiments as it also could reveal the concentration-dependent effect induced by PLA-DEX-OX4 nanoparticles (statistically significant for hCMEC/D3 cells at 4 mg/mL dose, compared with controls; ANOVA p < 0.05).
Figure 10
Translocation studies utilised the concentration of fluorescently labelled dextran (FITC-dextran) present in the apical compartment of the Transwell system as the indicator of the permeation enhancing properties of nanoparticles under investigation. The apparent permeation coefficient (P app ), calculated from the concentration of FITC-dextran transported across a unit surface area of the barrier over a specified timescale, corresponds to the translocating capacity of a cellular monolayer of a population of the cell culture. 28 As determined from the amount of translocated FITC-DEX, the data presented in Table 3 suggest that over a 3 h incubation time PLA-DEX-OX4
nanoparticles at high doses are more effective at modulating the permeability of hCMEC/D3 cell monolayers as compared with PLA-DEX nanoparticles. Since toxicity experiments have demonstrated that at relatively short incubation times the alkylglyceryl modification is not associated with any additional toxicity effects to cells (Figure 6B ), the increased transport of FITC-DEX cannot be readily attributed to cell death (and the consequent development of "leaky holes" in the monolayers); increased cytotoxicity is however noticeable with high doses (4 mg/ml) at long incubation times (> 72 h). While PLA-DEX nanoparticles were seen to increase the transport of FITC-DEX to some extent (possibly via non-specific nanoparticle-cell interaction), 40 data appear to support the hypothesis that the alkylglyceryl modification could possibly increase barrier permeability via mediated opening of the tight junctions. This is further supported by data from ECIS experiments, which revealed transient drops in TEER values upon the application of nanoparticles.
Table 3
Lower P app values were obtained for the hCMEC/D3 cell model than for that employing bEnd3 cells (Table 3) , which indicates the better barrier properties of the human brain cells model. While our P app values obtained with the mouse cell model were consistent with literature values (1 × 10 -7 at 4 h of incubation), 41 those for the human cell model are different. 42, 43 This may be explained in terms of the modifications in experimental protocol or may be consequent to the introduction of nonphysiologically relevant features into the system. 44, 45 Irrespective of the reason for this difference,
our results indicate that the use of a barrier enhancing formulation to decrease the permeability of the cell monolayers is effective.
Conclusions
Alkylglyceryl-modified dextran-graft-poly(lactic acid) derivatives (PLA-DEX-OXn; prepared by the alkylglycerol functionalisation of dextran and its subsequent attachment to the terminal carboxylic group of poly(lactic acid) by means of carbodiimide cross-linkers) can be easily formulated into nanoparticles that appear to be good candidates for drug delivery or for imaging applications.
Nanoparticles of average size in the 100-200 nm range exhibited unimodal size distribution profiles, as determined by DLS and NTA, and a negative zeta potential, as evidenced by electrophoretic mobility measurements. Formulations of these nanoparticles exhibit good stability at around neutral pH. The relative uniformity of nanoparticle size has been confirmed in the solid state by the SEM and AFM imaging of freeze dried samples. These nanoparticles may be prepared using any of three techniques (solvent displacement, nanoprecipitation or electrospraying) and are amenable to loading with actives or with fluorescent markers; the electrospraying technique has been identified as particularly useful for the loading of Doxorubicin.
In general, nanoformulations displayed low toxicity against mouse bEnd3 and human hCMEC/D3 brain endothelial cells, even at relatively high doses (80 % viability for 2 mg/mL, after 24 h incubation). However, over prolonged incubation times (> 72 h), doses of nanoparticles at the 4 mg/ml level appeared to negatively affect the cell monolayers integrity. As assessed by investigations involving early development-stage chicken embryos, PLA-DEX-OX4 nanoparticles did not exhibit any propensity to aggregation in blood circulation. Alkylglyceryl functionalisation has been shown to impact little upon the toxicity of nanoparticles, as assessed by comparative studies involving their unmodified congeners at similar concentrations. 
